Translate
Rallybio Corp
About
Rallybio Corp (NASDAQ:RLYB) — investor relations, events, news, and company updates on 6ix.
Latest News
Mar 2 2026
Rallybio Corporation and Candid Therapeutics Announce Merger Agreement
Feb 17 2026
Rallybio Announces Positive Data for RLYB116 Phase 1 Study Demonstrating Complete and Sustained Inhibition of Terminal Complement
Feb 3 2026
Rallybio Announces Reverse Stock Split of Common Stock
Nov 6 2025
Rallybio Reports Third Quarter 2025 Financial Results and Provides Business Updates
Sep 25 2025
Rallybio Completes Dosing of First Cohort in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study
Recent Videos
Rallybio & Candid Therapeutics: A Game-Changing Merger! #BiotechMerger #Pharmaceuticals #Investing
Mar 31, 2026
RLYB STOCK : POTENTIAL RECOVERY | RALLYBIO STOCK
Mar 27, 2026
BIG PRICE RECOVERY | RLYB STOCK ANALYSIS | RALLYBIO STOCK
Mar 05, 2026
Rallybio Corporation Conference Call on Merger of Rallybio and Candid Therapeutics | Mar 02, 2026
Mar 03, 2026
Financials
Revenue
$858 K
Market Cap
$44.59 M
EPS
-1.59